Topical Acyclovir Cream is NOT Effective for Genital Herpes and Should NOT Be Used
Topical acyclovir cream is substantially less effective than oral acyclovir for treating genital herpes and its use is discouraged 1. You should prescribe oral acyclovir instead.
Why Topical Acyclovir Fails in Clinical Practice
The CDC guidelines are unequivocal on this point: while randomized trials show that systemic (oral) acyclovir provides partial control of genital herpes symptoms, topical therapy with acyclovir is substantially less effective than the oral drug 1. This is the definitive guideline recommendation that should guide your prescribing.
The Evidence Behind This Recommendation
While older research studies from the early 1980s showed some statistical benefit of topical acyclovir cream in controlled trial settings 2, 3, 4, 5, 6, these modest laboratory findings did not translate into meaningful clinical utility. The studies showed:
- For first episodes: Reduced viral shedding duration (2-4 days vs 4.6-11 days with placebo) and faster healing (8-11 days vs 14-16 days) 2, 3, 5
- For recurrent episodes: Minimal to no benefit, particularly in women 5, 6
However, these marginal benefits pale in comparison to oral therapy, which is why guidelines explicitly discourage topical use.
What You Should Prescribe Instead
For First Clinical Episode of Genital Herpes:
- Acyclovir 200 mg orally 5 times daily for 7-10 days (or until clinical resolution) 1
For Recurrent Episodes (if treating):
- Acyclovir 400 mg orally 3 times daily for 5 days, OR
- Acyclovir 200 mg orally 5 times daily for 5 days, OR
- Acyclovir 800 mg orally 2 times daily for 5 days 7
A 2-day course of acyclovir 800 mg three times daily has also been shown effective for recurrent episodes 8.
For Daily Suppressive Therapy (≥6 recurrences/year):
Critical Clinical Pearls
Common Pitfall: Patients may request topical therapy thinking it's "safer" or more convenient. Explain that topical acyclovir simply doesn't work well enough because it doesn't achieve adequate systemic drug levels to suppress viral replication in nerve ganglia where HSV resides.
Important Caveat: Most immunocompetent patients with recurrent genital herpes don't benefit significantly from episodic treatment unless started during prodrome or within 1-2 days of lesion onset 1, 7. Since early treatment is rarely feasible, consider suppressive therapy for patients with frequent recurrences instead.
Gender Differences: The limited benefit seen with topical acyclovir was greater in females than males 2, but this doesn't change the recommendation—oral therapy is superior for both sexes.
The Bottom Line Algorithm
- First episode genital herpes → Oral acyclovir 200 mg 5x/day for 7-10 days
- Recurrent episodes with ≥6 episodes/year → Daily suppressive therapy (acyclovir 400 mg twice daily)
- Recurrent episodes with <6 episodes/year → Patient-initiated episodic therapy (acyclovir 400 mg 3x/day for 5 days) if they can start within 24 hours of symptom onset
- Topical acyclovir cream → Never use for genital herpes
The FDA label for oral acyclovir confirms its indication for initial episodes and management of recurrent genital herpes 9, while topical formulations are not indicated for this use.